Quarter
Charts

ABBOTT LABORATORIES

ABT

CIK 0000001800 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$11.46B
↑+4.4% +$485Mvs FY2024 (Q4)
Operating Income
$2.25B
↑+17.8% +$340Mvs FY2024 (Q4)
Net Income
$1.78B
↑+0.1% +$1Mvs FY2024 (Q4)
Gross Profit
$6.54B
↑+8.4% +$505Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
51/100
  • Profitability
    24ROIC 9.8% (10% = solid, 20%+ = moat)
  • Liquidity
    54Current Ratio 1.58 (above 1.5 = solid)
  • Leverage
    88D/E 0.25 (under 0.5 = conservative)
  • Efficiency
    25Asset Turnover 0.53x (1.0+ = capital-efficient)
  • Growth
    31Revenue YoY +4.4% (10% = solid, 25%+ = elite)
  • Margin Trend
    82Op Margin 19.6% · trend +1.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project ABT's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

3%

Trailing 3-yr CAGR was -1.8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$59.06
Total enterprise IV
$103.24B
Diluted shares
1.75B
Terminal PV
$72.75B (70% of total)
Year-5 FCF
$8.57B
YearProjected FCFDiscounted PV
+1$7.62B$6.92B
+2$7.85B$6.48B
+3$8.08B$6.07B
+4$8.32B$5.68B
+5$8.57B$5.32B
Terminal$117.16B$72.75B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$2.17B
investment in PP&E
Dividends paid (TTM)
$4.12B
cash returned to holders
Stock buybacks (TTM)
$893M
share count reduction
Stock-based comp (TTM)
$664M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$86.71B
everything owned
Stockholders' equity
$52.13B
shareholder claim
Net debt
$4.41B
LT debt minus cash

Recent performance · 72 quarters

Revenue↑+4.4% +$485M
$11.46B
Net Income↓-80.8% -$7.45B
$1.78B
Free Cash Flow↑+22.3% +$478M
$2.63B
Operating Margin↑+2.2pts
19.6%

Drill down

ABT Sankey

See ABBOTT LABORATORIES's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

ABT Charts

72 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

ABT Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics